Table 1 Characteristics of the study cohorts used in APOE genotyping
RECOVID | AUTOPSY | |||||
|---|---|---|---|---|---|---|
Group NOCOV | Group ICU | Group WARD | Group HOME | All COVID-19 + (ICU & WARD & HOME) | Group AUTOPSY | |
% (n) | % (n) | % (n) | % (n) | % (n) | % (n) | |
N = 53 | N = 58 | N = 33 | N = 37 | N = 128 | N = 21 | |
Female Sex | 49% (26) | 47% (27) | 67% (22) | 73% (27) | 59% (76) | 33% (7) |
Age, median (IQR) | 56 (50–64) | 63.5 (55.25–69.75) | 59 (53–65) | 46 (37–55) | 58 (47–66) | 71 (59–71) |
Age categories | ||||||
21–40 years | 9% (5) | 3% (2) | 6% (2) | 35% (13) | 13% (17) | 10% (2) |
41–60 years | 58% (31) | 31% (18) | 52% (17) | 49% (18) | 41% (53) | 19% (4) |
> 60 years | 32% (17) | 66% (38) | 42% (14) | 16% (6) | 45% (58) | 71% (15) |
BMI, median (IQR) | 26.9 (23.3–28.9)a | 29.8 (27.3–32.1) | 29.0 (24.8–33.1)b | 26.1 (23.4–28.5)c | 28.6 (25.0–31.6) | |
Any comorbidity | 32% (17) | 81% (47) | 79% (26) | 49% (18) | 71% (91) | |
Asthma | 0% (0) | 16% (9) | 30% (10) | 5% (2) | 16% (21) | |
Hypertension | 13% (7) | 50% (29) | 33% (11) | 14% (5) | 35% (45) | 81% (17) |
Diabetes | 2% (1) | 28% (16) | 6% (2) | 3% (1) | 15% (19) | 19% (4) |
Chronic Heart Disease | 2% (1) | 19% (11) | 3% (1) | 11% (4) | 13% (16) | |
Hypercholesterolemia | 11% (6) | 33% (19) | 12% (4) | 3% (1) | 19% (24) | |
Current or prior smokerd | 48% (28) | 30% (10) | ||||
APOE ε4 carrier | 39.6% (21) | 34.5% (20) | 42.4% (14) | 37.8% (14) | 37.5% (48) | 29% (6) |
APOE ε4ε4 genotype | 5.7% (3) | 3.4% (2) | 9.1% (3) | 8.1% (3) | 6.3% (8) | 4.8% (1) |